S. Chèze

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Andréa Toma, Olivier Kosmider, Sylvie Chevret et al. · Leukemia · 2015 · 120 citations · Full text

Hematological Malignancy, Transfusion Medicine, Hematology +4

High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study

Lionel Mannone, Claude Gardin, M.C. Quarré et al. · British Journal of Haematology · 2006 · 100 citations

Hematological Malignancy, Thrombosis, High‐dose Darbepoetin Alpha +15

A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia

M. Khellaf, J.-F. Viallard, M. Hamidou et al. · Haematologica · 2013 · 93 citations · Full text

Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.

Christian Rosé, Sabine Bréchignac, D. Vassilief et al. · Blood · 2007 · 73 citations

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

Charikleia Kelaïdi, Sophie Park, Rosa Sapena et al. · Leukemia · 2013 · 71 citations

Hematological Malignancy, Thrombosis, Erythropoiesis-stimulating Agents +9